A clinician perspective on the treatment of chronic myeloid leukemia in the chronic phase.
Chronic myeloid leukemia
First-line treatment
Treatment switching
Treatment-free remission
Tyrosine kinase inhibitors
Journal
Journal of hematology & oncology
ISSN: 1756-8722
Titre abrégé: J Hematol Oncol
Pays: England
ID NLM: 101468937
Informations de publication
Date de publication:
11 07 2022
11 07 2022
Historique:
received:
10
03
2022
accepted:
02
06
2022
entrez:
11
7
2022
pubmed:
12
7
2022
medline:
14
7
2022
Statut:
epublish
Résumé
Tyrosine kinase inhibitors (TKIs) have vastly improved long-term outcomes for patients with chronic myeloid leukemia (CML). After imatinib (a first-generation TKI), second- and third-generation TKIs were developed. With five TKIs (imatinib, dasatinib, bosutinib, nilotinib, and ponatinib) targeting BCR::ABL approved in most countries, and with the recent approval of asciminib in the USA, treatment decisions are complex and require assessment of patient-specific factors. Optimal treatment strategies for CML continue to evolve, with an increased focus on achieving deep molecular responses. Using clinically relevant case studies developed by the authors of this review, we discuss three major scenarios from the perspective of international experts. Firstly, this review explores patient-specific characteristics that affect decision-making between first- and second-generation TKIs upon initial diagnosis of CML, including patient comorbidities. Secondly, a thorough assessment of therapeutic options in the event of first-line treatment failure (as defined by National Comprehensive Cancer Network and European LeukemiaNet guidelines) is discussed along with real-world considerations for monitoring optimal responses to TKI therapy. Thirdly, this review illustrates the considerations and importance of achieving treatment-free remission as a treatment goal. Due to the timing of the writing, this review addresses global challenges commonly faced by hematologists treating patients with CML during the COVID-19 pandemic. Lastly, as new treatment approaches continue to be explored in CML, this review also discusses the advent of newer therapies such as asciminib. This article may be a useful reference for physicians treating patients with CML with second-generation TKIs and, as it is focused on the physicians' international and personal experiences, may give insight into alternative approaches not previously considered.
Identifiants
pubmed: 35818053
doi: 10.1186/s13045-022-01309-0
pii: 10.1186/s13045-022-01309-0
pmc: PMC9272596
doi:
Substances chimiques
Antineoplastic Agents
0
Protein Kinase Inhibitors
0
Imatinib Mesylate
8A1O1M485B
Dasatinib
RBZ1571X5H
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
90Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Informations de copyright
© 2022. The Author(s).
Références
Lancet Haematol. 2019 Jul;6(7):e375-e383
pubmed: 31201085
Curr Oncol Rep. 2021 Aug 3;23(10):114
pubmed: 34342734
Front Oncol. 2021 Mar 10;11:631570
pubmed: 33777785
Cancer Med. 2020 Jun;9(12):4160-4165
pubmed: 32319737
J Clin Oncol. 2018 Jan 20;36(3):231-237
pubmed: 29091516
Br J Haematol. 2021 Jan;192(1):62-74
pubmed: 32449159
Blood. 2021 Nov 25;138(21):2031-2041
pubmed: 34407542
J Clin Oncol. 2007 Sep 1;25(25):3908-14
pubmed: 17761974
Blood. 2017 Feb 16;129(7):846-854
pubmed: 27932374
Leukemia. 2020 Apr;34(4):966-984
pubmed: 32127639
Blood. 2021 Nov 25;138(21):2042-2050
pubmed: 34407543
Leukemia. 2021 May;35(5):1344-1355
pubmed: 33707652
J Manag Care Spec Pharm. 2017 Feb;23(2):214-224
pubmed: 28125373
Blood. 2009 Jun 18;113(25):6315-21
pubmed: 19369233
Cancer Med. 2020 Dec;9(23):8931-8939
pubmed: 33037866
Cancer. 2017 Nov 15;123(22):4403-4410
pubmed: 28743166
Front Oncol. 2020 Sep 02;10:1428
pubmed: 33014780
Blood. 2014 Feb 27;123(9):1353-60
pubmed: 24335106
J Clin Oncol. 2017 Jan 20;35(3):298-305
pubmed: 28095277
Blood Adv. 2020 Jul 14;4(13):3034-3040
pubmed: 32614963
Leuk Res. 2018 Jun;69:94-99
pubmed: 29734071
Blood. 2018 Jul 26;132(4):393-404
pubmed: 29567798
Blood. 2015 Jul 2;126(1):42-9
pubmed: 25918346
Indian J Hematol Blood Transfus. 2019 Jan;35(1):37-42
pubmed: 30828146
Br J Haematol. 2023 Sep 11;:
pubmed: 37697469
Pharmacoeconomics. 2007;25(6):481-96
pubmed: 17523753
Clin Cancer Res. 2017 Dec 1;23(23):7180-7188
pubmed: 28939746
Leukemia. 2015 Sep;29(9):1939-42
pubmed: 25676420
Nature. 2017 Mar 30;543(7647):733-737
pubmed: 28329763
Cancer Cell. 2019 Oct 14;36(4):431-443.e5
pubmed: 31543464
Br J Haematol. 2008 May;141(5):745-7
pubmed: 18331365
Hematol Oncol. 2019 Dec;37(5):652-654
pubmed: 31321792
N Engl J Med. 2019 Dec 12;381(24):2315-2326
pubmed: 31826340
Eur J Haematol. 2018 Sep;101(3):291-296
pubmed: 29691899
Front Oncol. 2020 Dec 15;10:580759
pubmed: 33384954
Cancer Lett. 2013 Jun 1;333(1):32-5
pubmed: 23291359
Blood. 2013 Aug 8;122(6):872-84
pubmed: 23803709
J Clin Oncol. 2014 Feb 1;32(4):306-11
pubmed: 24366936
Leukemia. 2020 Aug;34(8):2064-2073
pubmed: 32265500
Lancet Haematol. 2016 Dec;3(12):e581-e591
pubmed: 27890073
Cancer Sci. 2018 Jan;109(1):182-192
pubmed: 29058817
Leuk Lymphoma. 2019 Jun;60(6):1485-1492
pubmed: 30668187
Clin Lymphoma Myeloma Leuk. 2017 Oct;17(10):684-695.e6
pubmed: 28807791
Lancet Haematol. 2015 May;2(5):e186-93
pubmed: 26688093
Leukemia. 2015 May;29(5):1104-14
pubmed: 25394714
J Clin Med. 2020 Dec 25;10(1):
pubmed: 33375572
Am J Clin Oncol. 2020 Jul;43(7):517-525
pubmed: 32304434
Ann Oncol. 2012 Oct;23 Suppl 7:vii72-7
pubmed: 22997458
Mediterr J Hematol Infect Dis. 2021 Jan 01;13(1):e2021004
pubmed: 33489043
Leuk Lymphoma. 2020 Mar;61(3):650-659
pubmed: 31647335
J Clin Oncol. 2016 Aug 20;34(24):2851-7
pubmed: 27325849
Ann Intern Med. 2018 Apr 3;168(7):461-470
pubmed: 29459949
Blood. 2013 Jul 25;122(4):515-22
pubmed: 23704092
J Glob Oncol. 2016 Jul 20;3(1):64-71
pubmed: 28717743
Br J Haematol. 2020 Apr;189(2):303-312
pubmed: 32012231
Am J Hematol. 2015 Oct;90(10):910-4
pubmed: 26178642
Haematologica. 2014 Mar;99(3):437-47
pubmed: 24598855
Exp Hematol. 2019 Sep;77:36-40.e2
pubmed: 31493432
Circ Res. 2016 May 27;118(11):1723-35
pubmed: 27230638
Leukemia. 2021 Feb;35(2):440-453
pubmed: 33414482
Clin Lymphoma Myeloma Leuk. 2018 May;18(5):353-360.e1
pubmed: 29610029
Eur J Clin Pharmacol. 2020 Sep;76(9):1213-1226
pubmed: 32488333
N Engl J Med. 2010 Jun 17;362(24):2251-9
pubmed: 20525993
J Cancer Res Clin Oncol. 2018 May;144(5):945-954
pubmed: 29468438
Leukemia. 2016 May;30(5):1044-54
pubmed: 26837842
Curr Med Res Opin. 2010 Jan;26(1):61-9
pubmed: 19905880
N Engl J Med. 2010 Jun 17;362(24):2260-70
pubmed: 20525995
Leuk Res. 2013 May;37(5):487-95
pubmed: 23391518
J Cancer Res Clin Oncol. 2017 Jul;143(7):1167-1176
pubmed: 28289895
Clin Cancer Res. 2021 Jan 1;27(1):70-77
pubmed: 32928796
Haematologica. 2012 Jul;97(7):1029-35
pubmed: 22271898
J Clin Oncol. 2016 Jul 10;34(20):2333-40
pubmed: 27217448
J Hematol Oncol. 2019 Jan 3;12(1):1
pubmed: 30606227
Lancet Oncol. 2018 Jun;19(6):747-757
pubmed: 29735299
Blood. 2012 Mar 1;119(9):1981-7
pubmed: 22228624
J Clin Oncol. 2010 May 10;28(14):2381-8
pubmed: 20385986
Am J Hematol. 2019 Jan;94(1):46-54
pubmed: 30290003
Br J Haematol. 2019 Nov;187(4):543-545
pubmed: 31584727
J Natl Cancer Inst. 2022 Jan 11;114(1):160-164
pubmed: 34491344